Literature DB >> 17082574

Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8+ T cells.

Joanna N Radcliffe1, Joanne S Roddick, Peter S Friedmann, Freda K Stevenson, Stephen M Thirdborough.   

Abstract

The route for presentation of Ag to CD8+ or CD4+ T cells following DNA vaccination is critical for determining outcome, but the pathways involved are unclear. In this study, we compare two different DNA vaccine designs aimed to elicit CD8+ T cell responses against a specific peptide-epitope either by direct- or cross-presentation. Each carries sequences from tetanus toxin (TT) to provide essential CD4+ T cell help. In the first already proven design, the peptide-epitope is fused to the N-terminal domain of fragment C from TT. This appears to act mainly by cross-presentation. In the second design, the peptide-epitope is encoded by a minigene, with induction of Th responses mediated by coexpression of a hybrid invariant chain molecule, incorporating a single determinant from TT (p30) in exchange for class II-associated invariant chain peptide. This design appears to act mainly via direct presentation from transfected APCs. Both vaccines mediated Th-dependent priming of CD8+ T cells in mice, but the kinetics and level of the responses differed markedly, consistent with engagement of distinct pathways of Ag presentation. Importantly, the vaccines could be combined in an alternating prime-boost regime, in either order, generating substantially expanded memory CD8+ T cells, with potent effector function. Taken together, these results demonstrate that vaccination protocols involving different modes of Ag presentation at prime and boost can significantly improve the effectiveness of immunization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082574     DOI: 10.4049/jimmunol.177.10.6626

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Transgene expression and local tissue distribution of naked and polymer-condensed plasmid DNA after intradermal administration in mice.

Authors:  R Noelle Palumbo; Xiao Zhong; David Panus; Wenqing Han; Weihang Ji; Chun Wang
Journal:  J Control Release       Date:  2012-01-24       Impact factor: 9.776

2.  The impact of a boosting immunogen on the differentiation of secondary memory CD8+ T cells.

Authors:  Avi-Hai Hovav; Michael W Panas; Christa E Osuna; Mark J Cayabyab; Patrick Autissier; Norman L Letvin
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

3.  In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses.

Authors:  Qingtao Wang; Wei Jiang; Yuhai Chen; Pengyu Liu; Chunjie Sheng; Shuai Chen; Hui Zhang; Changchuan Pan; Shijuan Gao; Wenlin Huang
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

4.  Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice.

Authors:  Arash Arashkia; Farzin Roohvand; Arash Memarnejadian; Mohammad Reza Aghasadeghi; Sima Rafati
Journal:  Virus Genes       Date:  2009-10-31       Impact factor: 2.332

5.  DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.

Authors:  Geoffrey J Gorse; Mark J Newman; Allan deCamp; Christine Mhorag Hay; Stephen C De Rosa; Elizabeth Noonan; Brian D Livingston; Jonathan D Fuchs; Spyros A Kalams; Farah L Cassis-Ghavami
Journal:  Clin Vaccine Immunol       Date:  2012-03-07

6.  Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines.

Authors:  Zhidong Hu; Weimin Jiang; Ling Gu; Dan Qiao; Tsugumine Shu; Douglas B Lowrie; Shui-Hua Lu; Xiao-Yong Fan
Journal:  J Mol Med (Berl)       Date:  2019-11-30       Impact factor: 4.599

7.  Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.

Authors:  José Luis Nájera; Carmen Elena Gómez; Juan García-Arriaza; Carlos Oscar Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

8.  DNA fusion gene vaccination mobilizes effective anti-leukemic cytotoxic T lymphocytes from a tolerized repertoire.

Authors:  Jason Rice; Michelle L Dossett; Claes Ohlén; Sarah L Buchan; Timothy J Kendall; Stuart N Dunn; Freda K Stevenson; Philip D Greenberg
Journal:  Eur J Immunol       Date:  2008-08       Impact factor: 5.532

9.  Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine.

Authors:  Hong Chen; Xia Chuai; Yao Deng; Bo Wen; Wen Wang; Shaoqing Xiong; Li Ruan; Wenjie Tan
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

Review 10.  Methods for improving the immunogenicity and efficacy of cancer vaccines.

Authors:  Lorenzo Pilla; Soldano Ferrone; Cristina Maccalli
Journal:  Expert Opin Biol Ther       Date:  2018-06-17       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.